Evidence map›Paper›PMID 27160653›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016

Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States.

S Karami, E L Yanik, L E Moore, R M Pfeiffer, G Copeland, L Gonsalves, B Y Hernandez, C F Lynch, K Pawlish, E A Engels

Abstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Population-level cancer trends among solid organ transplant recipients in the United States during 1995-2021.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  5. Article
  6. Review
  7. Solid masses arising in transplanted kidneys.Abdominal radiology (New York) · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Edible mushroom (Anatomy & cell biology · 2024
    Article
  18. Article
  19. Article
  20. Monogenic Kidney Diseases in Kidney Transplantation.Kidney international reports · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

S KaramiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD.
E L YanikDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD.
L E MooreDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD.
R M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD.
G CopelandMichigan Cancer Surveillance Program, Michigan Department of Community Health, Lansing, MI.
L GonsalvesConnecticut Department of Public Health, Hartford, CT.
B Y HernandezUniversity of Hawaii Cancer Center, Honolulu, HI.
C F LynchDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA.
K PawlishNew Jersey State Cancer Registry, Cancer Epidemiology Services, New Jersey Department of Health, Trenton, NJ.
E A EngelsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Department of Health and Human Services, Bethesda, MD.
National Cancer Institute · USConnecticut Department of Public Health · USMichigan Department of Health and Human Services · USNew Jersey Department of Health · USUniversity of Hawaii Cancer CenterUniversity of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
NATIONAL CANCER PREVENTION AND CONTROL PROGRAMU58DP000824 · DP · TEXAS STATE DEPT OF HEALTH SERVICES · PI DELGADO, EVELYN · 2007 to 2011
$44.3M
NEW YORK STATE CANCER PREVENTION & CONTROL PROGRAMU58DP003879 · DP · NYSDOH/HEALTH RESEARCH, INC. · PI WALLACE, BARBARA J · 2012 to 2014
$37.6M
MICHIGAN CANCER PREVENTION & CONTROL PROGRAMU58DP003921 · DP · MICHIGAN STATE DEPARTMENT OF HEALTH AND HUMAN SERVICES · PI BROOKOVER, PATRICIA · 2012 to 2014
$30.7M
Category A - Communities Putting Prevention to WorkU58DP000848 · DP · COLORADO STATE DEPT/PUB HLTH & ENVIRONMT · PI JACOBELLIS, JILLIAN · 2007 to 2011
$25.9M
Infections, immunity, and inflammation in cancerZIACP010150 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2009 to 2025
$24.0M
NATIONAL CANCER PREVENTION AND CONTROL PROGRAMU58DP000832 · DP · NC STATE DEPT/HLTH & HUMAN SERVICES · PI PETERSEN, RUTH · 2007 to 2011
$23.6M
NATIONAL CANCER PREVENTION & CONTROL PROGRAM - ILLINOISU58DP003883 · DP · ILLINOIS STATE DEPT OF PUBLIC HEALTH · PI MOODY, CONNY · 2012 to 2014
$22.6M
CALIFORNIA'S PARTICIPATION IN THE NATIONAL CANCER PREVENTION AND CONTRO PROGRAMU58DP000807 · DP · PUBLIC HEALTH INSTITUTE · PI SNIPES, KURT P · 2007 to 2011
$22.5M
GEORGIA COMPREHENSIVE CANCER CONTROL PROGRAMU58DP003875 · DP · GEORGIA DIVISION OF PUBLIC HEALTH · PI O'CONNOR, JEAN CATHERINE · 2012 to 2014
$15.9M
NEW JERSEY CANCER PREVENTION & CONTROL PROGRAMU58DP003931 · DP · NEW JERSEY STATE DEPT/HEALTH/SENIOR SRVS · PI RODRIQUEZ, GLORIA · 2012 to 2014
$11.9M
MASSACHUSETTS CANCER PREVENTION & CONTROL PROGRAMU58DP003920 · DP · MASSACHUSETTS STATE DEPT OF PUB HEALTH · PI NYAMBOSE, JOSHUA · 2012 to 2014
$11.4M
CCR NIH HHS HHSN261201300011CIntramural NIH HHS Z99 CA999999NCCDPHP CDC HHS U58 DP000807NCCDPHP CDC HHS U58 DP000824NCCDPHP CDC HHS U58 DP000832NCCDPHP CDC HHS U58 DP000848NCCDPHP CDC HHS U58 DP003875NCCDPHP CDC HHS U58 DP003879NCCDPHP CDC HHS U58 DP003883NCCDPHP CDC HHS U58 DP003920NCCDPHP CDC HHS U58 DP003921NCCDPHP CDC HHS U58 DP003931NCI NIH HHS HHSN261201000024CNCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000035INCI NIH HHS HHSN261201000036CNCI NIH HHS HHSN261201000037CNCI NIH HHS HHSN261201300021CNCI NIH HHS HHSN261201300071CNCI NIH HHS N01 PC035137NCI NIH HHS N01 PC035139NCI NIH HHS N01 PC035142NCI NIH HHS N01 PC035143
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is a common malignancy following kidney transplantation. We describe RCC risk and examine RCC risk factors among US kidney recipients (1987-2010). The Transplant Cancer Match Study links the US transplant registry with 15 cancer registries. Standardized incidence ratios (SIRs) were used to compare RCC risk (overall and for clear cell [ccRCC] and papillary subtypes) to the general population. Associations with risk factors were assessed using Cox models. We identified 683 RCCs among 116 208 kidney recipients. RCC risk was substantially elevated compared with the general population (SIR 5.68, 95% confidence interval 5.27-6.13), especially for papillary RCC (SIR 13.3 versus 3.98 for ccRCC). Among kidney recipients, RCC risk was significantly elevated for blacks compared to whites (hazard ratio [HR] 1.50) and lower in females than males (HR 0.56). RCC risk increased with prolonged dialysis preceding transplantation (p-trend < 0.0001). Risk was variably associated for RCC subtypes with some medical conditions that were indications for transplantation: ccRCC risk was reduced with polycystic kidney disease (HR 0.54), and papillary RCC was increased with hypertensive nephrosclerosis (HR 2.02) and vascular diseases (HR 1.86). In conclusion, kidney recipients experience substantially elevated risk of RCC, especially for papillary RCC, and multiple factors contribute to these cancers.

Indexed as

Postoperative ComplicationsAdultCarcinoma, Renal CellFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionHumansIncidenceKidney Failure, ChronicKidney Function TestsKidney NeoplasmsKidney TransplantationMaleMiddle AgedPrognosiscancer/malignancy/neoplasia: risk factorsepidemiologyhealth services and outcomes researchkidney transplantation/nephrology

Identifiers

PMID27160653
PMCPMC5104677
OpenAlexW2390429261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.